After Eli Lilly's Flop, Could Alzheimer's Become Healthcare's Trumpshot?

If the healthcare industry’s approach to Alzheimer’s disease were a building project, it could best be described as constructing a skyscraper from the top down–possible, yet at best impractical. Last week Eli Lilly and Company announced that the company’s Alzheimer’s drug solanezumab, which is intended to reduce amyloid plaque, failed to help Alzheimer’s patients recover or maintain their mental acuity in a late-stage trial.